Strategic Expansion Target diagnostic and CLIA-certified laboratories expanding autoimmune and infectious disease testing, leveraging Enable Biosciences' ultrasensitive immunoassays and recent FDA-ready ADAP platform partnerships to accelerate adoption.

Clinical Kit Growth capitalize on the January 2024 kit to clinics initiative by offering bundled assays, automation-ready workflows, and training services to clinics and hospital networks seeking streamlined autoimmune and diabetes testing.

High-Growth Funding Leverage recent SBIR funding and new CFO appointment to engage grant-facing buyers and strategic investors, proposing co-development projects and government-funded pilot programs to broaden market reach.

High-Throughput Readiness Position the ADAP STAR platform and Hamilton Robotics partnership as a turnkey solution for high-throughput population screening programs, targeting blood banks, screening labs, and large health systems.

Key Thought Leaders Highlight the Nobel Prize connection of co-founders to build credibility with academic medical centers and translational research networks, using co-branding and sponsored symposia to open new collaboration and procurement discussions.